Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions
Paroxysmal Atrial Fibrillation
Interventions
DRUG

antazoline

Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.

DRUG

0.9% saline

Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.

Trial Locations (1)

02-637

Institute of Cardiology, II Dept. of Coronary Heart Disease, Warsaw

All Listed Sponsors
lead

National Institute of Cardiology, Warsaw, Poland

OTHER

NCT01527279 - Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation | Biotech Hunter | Biotech Hunter